Oxford Immunotec Global (NASDAQ:OXFD) reported Q4 2017 earnings this Morning, coming in at ($0.33) per share, beating Wall Street’s estimates of ($0.36) per Share. Revenue for the quarter came in at $25.03 million missing the streets estimates of $25.12 million Recent Insider Trading for Oxford Immunotec Global (NASDAQ:OXFD)
- On 2/16/2018 Richard A Sandberg, Director, sold 3,000 with an average share price of $12.01 per share and the total transaction amounting to $36,030.00.
- On 11/1/2017 Richard A Sandberg, Director, sold 3,000 with an average share price of $13.35 per share and the total transaction amounting to $40,050.00.
- On 10/2/2017 Peter Wrighton-Smith, CEO, sold 55,000 with an average share price of $16.78 per share and the total transaction amounting to $922,900.00.
- On 9/1/2017 Richard A Sandberg, Director, sold 3,000 with an average share price of $15.82 per share and the total transaction amounting to $47,460.00.
- On 8/15/2017 Peter Edwardson, COO, sold 9,739 with an average share price of $16.14 per share and the total transaction amounting to $157,187.46.
- On 8/7/2017 Peter Edwardson, COO, sold 22,371 with an average share price of $17.70 per share and the total transaction amounting to $395,966.70.
Recent Trading for Oxford Immunotec Global (NASDAQ:OXFD) Shares of Oxford Immunotec Global closed the previous trading session at 11.62 down -0.38 3.17% with 11.899999618530273 shares trading hands.